- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT06307340
Adaptação da intervenção de trauma STAIR-NT para populações de polissubstâncias
During this 36-month R34 trial, eight study phases are proposed to adapt an evidence-based post traumatic stress disorder (PTSD) intervention (STAIR-NT) and layer it into a methadone maintenance treatment (MMT) program (START Treatment and Recovery centers) in New York City for use among individuals engaged in stimulant-opioid polysubstance use. The study aims to adapt STAIR-NT to a massed treatment schedule. Once an adapted protocol is complete, it will be tested for feasibility, acceptability, and short-term polysubstance and PTSD symptomology outcomes in a pilot randomized control trial (RCT) of 80 participants. Participants who screen eligible and consent will be randomized 1:1 to the adapted STAIR-NT intervention or treatment as usual (TAU) using randomization blocks of two and two and four via a computer-generated randomization sequence. Participants assigned to the intervention will receive the adapted massed delivery of STAIR-NT by trained counselors.
Visão geral do estudo
Status
Tipo de estudo
Inscrição (Real)
Estágio
- Não aplicável
Contactos e Locais
Locais de estudo
-
-
Florida
-
Tallahassee, Florida, Estados Unidos, 32306
- Florida State University
-
-
New York
-
Brooklyn, New York, Estados Unidos, 11238
- START Treatment and Recovery Centers
-
New York, New York, Estados Unidos, 10016
- NYU Langone Health
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- must be 18 years or older,
- be a patient at the START clinic receiving methadone for treatment of opioid use disorder,
- self-report 10+ days of co-use of cocaine and illicit opioids in the past 30-days,
- meet the criteria for stimulant use disorder (cocaine type; mild, moderate or severe) and a score of 3≥ on the PC-PTSD-5.
Exclusion Criteria:
- cognitive impairment that would interfere with their ability to understand study participation as assessed by the researcher,
- does not speak/understand English at a conversational level,
- plans to leave the START clinic in the next 60 days,
- patients who missed methadone doses (inactive) for 30 days or more, or
- having received clinical care from the interventionist(s) in the past 30 days
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Pesquisa de serviços de saúde
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Solteiro
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Comparador Ativo: Tratamento como de costume (TAU)
|
Treatment as usual. |
|
Experimental: Intervenção STAIR-NT Adaptada
|
Adapted version of evidence-based behavioral PTSD intervention. |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Número de sessões de intervenção concluídas
Prazo: Até o mês 3
|
Até o mês 3
|
|
|
Número de substâncias usadas com base na triagem de drogas na urina
Prazo: Mês 3
|
Mês 3
|
|
|
Número de substâncias utilizadas com base na abstração de gráficos de resultados toxicológicos
Prazo: Mês 3
|
Mês 3
|
|
|
Proportion of Eligible Participants
Prazo: Baseline
|
Proportion of persons eligible to enroll in the study of all possible MMT patients approached. Assessed using count data of individuals failing screen. |
Baseline
|
|
Proportion of Eligible Participants who Enroll
Prazo: Baseline
|
.Proportion of all eligible persons who enroll. Assessed using count data of individuals consented. |
Baseline
|
|
Clinician-Rated Feasibility of Intervention Measure (FIM) Score
Prazo: Month 3
|
4-item, clinician-rated assessment of the feasibility of the intervention. Each item is rated on a scale from 1 (Completely disagree) to 5 (Completely agree); the total score is the sum of responses and ranges from 4-20. Higher scores indicate greater clinician-rated feasibility. |
Month 3
|
|
Clinician-Rated Feasibility of Acceptability of Intervention Measure (AIM) Score
Prazo: Month 3
|
4-item, clinician-rated assessment of the acceptability of the intervention. Each item is rated on a scale from 1 (Completely disagree) to 5 (Completely agree); the total score is the sum of responses and ranges from 4-20. Higher scores indicate greater clinician-rated acceptability. |
Month 3
|
|
Number of Days of Co-Use of Cocaine and Illicit Opioids
Prazo: Month 3
|
Measured using the Addiction Severity Index (ASI) questionnaire. |
Month 3
|
|
Number of Substances Used based on ASI Self-Report
Prazo: Month 3
|
Measured using the Addiction Severity Index (ASI) questionnaire, a self-report assessment to gauge the severity of a person's substance abuse. |
Month 3
|
|
PTSD Checklist for DSM-5 (PCL-5) Score
Prazo: Month 3
|
The PCL-5 is a 20-item self-report measure that assesses the 20 DSM-5 symptoms of PTSD. Each item is rated on a scale from 0-4. A total symptom severity score (range - 0-80) can be obtained by summing the scores for each of the 20 items; higher scores indicate greater severity of PTSD. |
Month 3
|
|
Negative Mood Regulation Scale Score
Prazo: Month 3
|
30-item assessment of individuals' beliefs and expectations regarding their ability to regulate their negative mood and emotions. Each item is rated on a 5-point Likert scale ranging from 1 (not at all effective) to 5 (extremely effective). The total score ranges from 30-150; higher scores indicate more effective negative mood regulation. |
Month 3
|
|
Inventory of Interpersonal Problems Score
Prazo: Month 3
|
A 127-item, self-report inventory that asks participants to rate a variety of interpersonal problems that may cause distress. The items are divided into two groups: (1) interpersonal inadequacies or inhibitions (78 items), (2) excesses or compulsions (49 items). Participants rate each item on a scale from 0 to 4 on how much difficulty/distress they feel regarding the item. The total score is calculated by adding the item responses; lower scores indicate less difficulty/distress. |
Month 3
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Amanda Bunting, NYU Langone Health
Publicações e links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- 22-01058
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
Deidentified quantitative assessment data will be shared upon reasonable request beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research. Data will be stored in a data repository. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.
Prazo de Compartilhamento de IPD
Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research.
Critérios de acesso de compartilhamento IPD
The investigator who proposed to use the data will be granted access upon reasonable request. The data will be stored in a data repository.
Tipo de informação de suporte de compartilhamento de IPD
- PROTOCOLO DE ESTUDO
- SEIVA
- CIF
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .